ProMIS Neurosciences Financials - Benzinga

ProMIS Neurosciences Inc

PMNNASDAQ

Trade with Public

Trade with Public

$13.26

-0.30-2.21%

Last update: Sep 9, 9:00 AM

$14.00

0.443.24%

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

ProMIS Neurosciences Financials

ProMIS Neurosciences (PMN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of $(5.25) per share from

Benzinga Newsdesk

PRO
CORRECTION: ProMIS Neurosciences Q4 EPS $(3.11) Misses $(0.21) Estimate

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(3.11) per share which missed the analyst consensus estimate of $(0.21) by 1380.95 percent. This is a 522 percent decrease over losses of $(0.50) per share

Benzinga Newsdesk

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

Avi Kapoor

PRO
ProMIS Neurosciences Q3 EPS $(0.24), Inline

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 177.42 percent decrease over earnings of $0.31 per share from the same period last

Benzinga Newsdesk